GnTs play an important role in glycoprotein biosynthesis. It catalyzes the synthesis of complex glycans with multiple structures. Studies have shown that it mainly affects the synthesis of the O-glycan core structure and the branching of N-linked glycans on glycoproteins. The O-glycan and N-glycan structures are associated with a variety of diseases. GnT gene modification has become a new direction for the treatment of diseases such as diabetes, cancer, etc. In addition, by constructing GnT plant mutants or heterologous expressions of GnT, scientists obtain recombinant proteins with specific structures and functions for disease treatment. GnT gene modification can also be used to study the function of GnT in O-glycan and N-glycan synthesis.
At CD BioGlyco, our GnTs engineering service is crafted to deliver unmatched precision in regulating the glycosylation processes of your target proteins. Drawing on our extensive specialization in glycobiology and genetic engineering, we offer all-encompassing strategies to refine the glycan structures of biotherapeutic agents, enhance their therapeutic performance, and guarantee their safety profiles.
We use powerful gene editing tools to perform targeted knock-outs, knock-ins, and overexpression of specific GnT genes. By silencing unwanted endogenous GnT enzymes or overexpressing desired ones, we fundamentally redirect the glycan biosynthesis pathway toward producing a more homogenous and optimized glycoform.
CD BioGlyco is committed to combining Gene Editing with physiology and case phenotyping to study the function of genes and develop new directions for disease treatment. Our gene modification studies for GnTs involve different models such as mice, plants, and cancer cells.
Fig.1 Different directions of GnT gene modification. (CD BioGlyco)
Paper Title: Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer
Technology: Gene Overexpression, Gene Silencing
Journal: Journal of Clinical Investigation
IF: 15.9
Published: 2023
Results: Dolichyl-phosphate N-acetylglucosaminyltransferase (DPAGT1) maintains high levels of human epidermal growth factor receptor 2 (HER2) shedding, rendering trastuzumab resistant. DPAGT1 silencing significantly reduced HER2-ECD levels in the culture medium. Targeting DPAGT1 may be a promising strategy for the treatment of trastuzumab-resistant breast cancer.
Fig. 2 Regulatory effects of DPAGT1 on HER2 shedding. (Yang, et al., 2023)
CD BioGlyco is committed to providing global partners with experimental models rich in polysaccharides and high-level gene editing services. We have a high-level gene modification research team. In addition to GnT, we also provide Galactosyltransferase Engineering Service and N-Acetylgalactosaminyltransferase Engineering Service. If you have any need for gene modification-related experiments, please feel free to contact us.
We offer comprehensive analytical services to characterize the full glycan profile of any biological sample. These services are used to inform your engineering strategy or to confirm the results of your project.
As a specialized variant of our service, we provide targeted solutions for therapeutic antibodies, focusing on the Fc glycosylation site (Asn297) to precisely modulate effector functions.
For researchers working with bacterial-derived products, we provide detailed LPS characterization services designed to meet the rigorous demands of modern microbiology and immunology studies.
Reference